Previous 10 | Next 10 |
home / stock / ipsey / ipsey news
Sales growth of 26.7% 1 for Specialty Care and 2.0% 1,2 for Consumer Healthcare Core Operating Income growth of 34.1% Upgraded full year 2018 guidance of Group sales growth greater than 19.0% 1 (versus prior guidance greater than 16.0%) and Core operating margin of around 29.0% ...
Ipsen Innovation Center – BioLabs to be located in Ipsen’s new and third global hub in the heart of Cambridge, Massachusetts Regulatory News: Ipsen, a global biopharmaceutical group focused on innovation and specialty care, today announced an agreement with BioLabs...
Quick Take Constellation Pharmaceuticals ( CNST ) intends to raise gross proceeds of $80 million from a U.S. IPO, according to an S-1/A registration statement . The firm is a clinical-stage biopharmaceutical company which uses epigenetics, a regulatory system that controls gene expres...
– Trial results formed the basis of regulatory filings in the U.S. and European Union for CABOMETYX ® for previously treated advanced hepatocellular carcinoma (HCC) – Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced that The New En...
- Clinical research reaffirms Ipsen’s support for patients and the neuroscience community - Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced that its neurotoxin portfolio will be the subject of 13 abstracts at the 12th International Society of Physica...
Healthcare investors should strongly consider a long position in Exelixis ( EXEL ) while the company is beaten down. Irrational Mr. Market Oblivious & Overreacting When the market punished flat fourth-quarter Cabometyx revenues with a 13% drop, it must have overlooked management's ...
-- Ipsen commits to creating global hub in North America, expects to add more than 200 jobs -- Today, Ipsen (Euronext: IPN; ADR: IPSEY), a global biopharmaceutical group, announced it will establish its North American headquarters in Cambridge, Massachusetts. The announcement was made...
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY), announces today that it has appointed an investment services provider to purchase 250,000 Ipsen SA shares, or about 0.30% of the share capital, over a period of at least 3 months. The shares purchased under this agreement will be m...
Analysis Focus: CPRX Catalyst Pharmaceuticals (CPRX) is a smallcap company with $363M in market capitalization. The company was founded as Catalyst Pharmaceutical Partners, Inc. in 2002 and is based in Coral Gables, Florida. Their focus is on development and commercialization of therapies ...
Adoption of all resolutions submitted to the vote of Shareholders Regulatory News: The Combined Shareholders’ Meeting of Ipsen S.A. (Euronext: IPN; ADR: IPSEY), chaired by Marc de Garidel, Chairman of the Board, was held today, in the presence of the members of the Board of D...
News, Short Squeeze, Breakout and More Instantly...
Ipsen SA ADR Company Name:
IPSEY Stock Symbol:
OTCMKTS Market:
Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases Canada NewsWire Ipsen enters into an option agreement to receive exclusive global rights to two candidates pursued under the collaboration Following development ...
Marengo Therapeutics Announces First Drug Candidate Nomination from Oncology Collaboration with Ipsen PR Newswire A Novel TCR Vβ bifunctional selective T cell activator molecule for solid tumor treatment Marengo to receive an associated milestone payment a...
Turnstone Biologics Corp. (TSBX) is expected to report $-0.73 for Q4 2023 Exro Technologies Inc (EXROF) is expected to report for Q4 2023 Boyd Gaming Corporation (BYD) is expected to report $1.43 for Q4 2023 Onto Innovation Inc. (ONTO) is expected to report $0.99 for Q4 2023 Motor...